



PB 102 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 9) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 26 September 2024

Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 October 2024	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing immediately after the commencement of Schedule 2 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 4) 2024 – 1 October 2024</i>	15
<i>National Health (Minimum Stockholding) Determination 2023</i>	15
Schedule 3—Amendments commencing immediately after the commencement of Schedule 3 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024 – 1 December 2024</i>	16
<i>National Health (Minimum Stockholding) Determination 2023</i>	16

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 9) 2024*.
- (2) This instrument may also be cited as PB 102 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 October 2024.	1 October 2024
2. Schedule 1	1 October 2024.	1 October 2024
3. Schedule 2	Immediately after the commencement of Schedule 2 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 4) 2024</i> .	1 October 2024
4. Schedule 3	Immediately after the commencement of Schedule 3 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024</i> .	1 December 2024

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 October 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

Abacavir with lamivudine	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	Oral	ABACAVIR/LAMIVUDINE 600/300 SUN	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------------------	---	------	---------------------------------	---

2 Schedule 1 (table)

Before:

Acamprosate	Tablet (enteric coated) containing acamprosate calcium 333 mg	Oral	Acamprosate Viatris	after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together
-------------	---	------	---------------------	---

insert:

Abacavir with lamivudine	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	Oral	Abacavir/Lamivudine Viatris	after 31 December 2024—4 months stock by reference to usual demand of both Abacavir/Lamivudine Viatris and Abacavir/Lamivudine Mylan added together
--------------------------	---	------	-----------------------------	---

3 Schedule 1 (table)

After:

Acarbose	Tablet 50 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
----------	--------------	------	----------	---

insert:

Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol	Oral	Fosamax Plus 70 mg/140 mcg	between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand
-------------------------------------	---	------	----------------------------	--

Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol	Oral	Fosamax Plus	between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand
-------------------------------------	--	------	--------------	--

4 Schedule 1 (table)

Omit:

Amoxicillin	Capsule 500 mg (as trihydrate)	Oral	NOUMED AMOXICILLIN	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-------------	--------------------------------	------	-----------------------	---

5 Schedule 1 (table)

Omit:

Amoxicillin with clavulanic acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	AlphaClav Duo Forte Viartis	after 31 August 2024—6 months stock by reference to usual demand of both Alphaclav Duo Forte Viartis and AlphaClav Duo Forte added together
----------------------------------	---	------	--------------------------------	---

6 Schedule 1 (table)

After:

Amoxicillin	Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL	Oral	Amoxil	4 months stock by reference to usual PBS demand
-------------	---	------	--------	---

insert:

Amoxicillin with clavulanic acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	AlphaClav Duo Forte Viartis	6 months stock by reference to usual demand
----------------------------------	---	------	--------------------------------	---

7 Schedule 1 (table)

Omit:

Aripiprazole	Tablet 10 mg	Oral	Tevaripiprazole	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------	--------------	------	-----------------	---

8 Schedule 1 (table)

After:

Aripiprazole	Tablet 15 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
--------------	--------------	------	------------------	---

insert:

Aripiprazole	Tablet 15 mg	Oral	Aripic Aripiprazole	between 1 October 2024 and 31 March 2025—0 months
--------------	--------------	------	---------------------	---

stock by reference to usual demand

9 Schedule 1 (table)

Omit:

Aripiprazole	Tablet 15 mg	Oral	Tevaripiprazole	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------	--------------	------	-----------------	---

10 Schedule 1 (table)

After:

Aripiprazole	Tablet 20 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
--------------	--------------	------	------------------	---

insert:

Aripiprazole	Tablet 20 mg	Oral	Aripic Aripiprazole	between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand
--------------	--------------	------	---------------------	--

11 Schedule 1 (table)

Omit:

Aripiprazole	Tablet 20 mg	Oral	Tevaripiprazole	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------	--------------	------	-----------------	---

12 Schedule 1 (table)

After:

Aripiprazole	Tablet 30 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
--------------	--------------	------	------------------	---

insert:

Aripiprazole	Tablet 30 mg	Oral	Aripic Aripiprazole	between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand
--------------	--------------	------	---------------------	--

13 Schedule 1 (table)

Omit:

Aripiprazole	Tablet 30 mg	Oral	Tevaripiprazole	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------	--------------	------	-----------------	---

14 Schedule 1 (table)

Omit:

Atorvastatin	Tablet 80 mg (as calcium)	Oral	Atorvastatin GH	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------	---------------------------	------	-----------------	---

15 Schedule 1 (table)

After:

Benzathine benzylpenicillin	Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand
-----------------------------	--	-----------	--------------	---

insert:

Bisacodyl	Tablet 5 mg	Oral	Lax-Tab	between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand
-----------	-------------	------	---------	--

16 Schedule 1 (table)

Omit:

Carmellose	Eye drops containing carmellose sodium 10 mg per mL, 15 mL	Application to the Eye	Refresh Liquigel	4 months stock by reference to usual PBS demand
------------	--	------------------------	------------------	---

substitute:

Carmellose	Eye drops containing carmellose sodium 10 mg per mL, 15 mL	Application to the Eye	Refresh Liquigel	between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand
------------	--	------------------------	------------------	--

17 Schedule 1 (table)

Omit:

Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 15 mL	Application to the Eye	Refresh Tears Plus	4 months stock by reference to usual PBS demand
------------	---	------------------------	--------------------	---

substitute:

Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 15 mL	Application to the Eye	Refresh Tears Plus	between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand
------------	---	------------------------	--------------------	--

18 Schedule 1 (table)

Omit:

Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the Eye	Optive	4 months stock by reference to usual PBS demand
substitute:				
Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the Eye	Optive	between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand

19 Schedule 1 (table)

After:

Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cephazolin Viatrix	after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viatrix and Cephazolin Alphapharm added together
-----------	--------------------------------------	-----------	--------------------	--

insert:

Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime Kabi	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand
----------	---	-----------	---------------	---

Cefepime	Powder for injection 2 g (as hydrochloride)	Injection	Cefepime Kabi	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand
----------	---	-----------	---------------	---

20 Schedule 1 (table)

After:

Ciclosporin	Oral liquid 100 mg per mL, 50 mL	Oral	Neoral	4 months stock by reference to usual PBS demand
-------------	----------------------------------	------	--------	---

insert:

Ciprofloxacin	Tablet 250 mg (as hydrochloride)	Oral	APX-Ciprofloxacin	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
---------------	----------------------------------	------	-------------------	--

Ciprofloxacin	Tablet 500 mg (as hydrochloride)	Oral	APX-Ciprofloxacin	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
---------------	----------------------------------	------	-------------------	--

Ciprofloxacin	Tablet 750 mg (as hydrochloride)	Oral	APX-Ciprofloxacin	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
---------------	----------------------------------	------	-------------------	--

21 Schedule 1 (table)

Omit:

Ciprofloxacin	Tablet 500 mg (as hydrochloride)	Oral	Cifran	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
---------------	----------------------------------	------	--------	---

22 Schedule 1 (table)

Omit:

Cyproterone	Tablet containing cyproterone acetate 100 mg	Oral	Pharmacor Cyproterone 100	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-------------	--	------	---------------------------	---

Cyproterone	Tablet containing cyproterone acetate 50 mg	Oral	Pharmacor Cyproterone 50	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-------------	---	------	--------------------------	---

23 Schedule 1 (table)

Omit:

Donepezil	Tablet containing donepezil hydrochloride 10 mg	Oral	NOUMED DONEPEZIL	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-----------	---	------	------------------	---

Donepezil	Tablet containing donepezil hydrochloride 5 mg	Oral	NOUMED DONEPEZIL	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-----------	--	------	------------------	---

24 Schedule 1 (table)

Omit:

Enalapril	Tablet containing enalapril maleate 20 mg	Oral	Enalapril generichealth	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-----------	---	------	-------------------------	---

25 Schedule 1 (table)

After:				
Entecavir	Tablet 1 mg (as monohydrate)	Oral	ENTECLUDE	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
insert:				
Epoprostenol	Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL	Injection	Flolan	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand
Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL	Injection	Flolan	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand

26 Schedule 1 (table)

After:				
Escitalopram	Tablet 20 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
insert:				
Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	Oral	Esomeprazole Viatriis	after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatriis and Esomeprazole Mylan added together
Esomeprazole	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	Oral	Esomeprazole Viatriis	after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatriis and Esomeprazole Mylan added together

27 Schedule 1 (table)

Omit:				
Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	Oral	NOUMED ESOMEPRAZOLE	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
Esomeprazole	Tablet (enteric coated) 40 mg (as	Oral	NOUMED ESOMEPRAZOLE	between 1 August 2024 and 30

magnesium
trihydrate)

September 2024—0
months stock by
reference to usual
demand

28 Schedule 1 (table)

Omit:

Fenofibrate	Tablet 145 mg	Oral	Fenofibrate Viatris	6 months stock by reference to usual demand of both Fenofibrate Viatris and Fenofibrate Mylan added together
-------------	---------------	------	---------------------	--

29 Schedule 1 (table)

Omit:

Fluorometholone	Eye drops 1 mg per mL, 5 mL	Application to the Eye	FML Liquifilm	between 1 July 2024 and 31 January 2025—0 months stock by reference to usual demand
-----------------	--------------------------------	---------------------------	---------------	---

30 Schedule 1 (table)

Omit:

Gabapentin	Capsule 300 mg	Oral	Gabapentin generichealth	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
------------	----------------	------	-----------------------------	--

Gabapentin	Capsule 400 mg	Oral	Gabapentin generichealth	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
------------	----------------	------	-----------------------------	--

31 Schedule 1 (table)

Omit:

Hydrocortisone	Tablet 20 mg	Oral	Hydrocortisone Viatris 20	4 months stock by reference to usual demand of both Hydrocortisone Viatris 20 and Hydrocortisone Mylan 20 added together
----------------	--------------	------	------------------------------	---

32 Schedule 1 (table)

After:

Hypromellose	Eye drops 3 mg per mL, 10 mL	Application to the Eye	In a Wink Moisturising	between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand
--------------	------------------------------	------------------------	------------------------	--

insert:

Hypromellose with carbomer 980	Ocular lubricating gel 3 mg-2 mg per g, 10 g	Application to the Eye	Genteal gel	between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand
--------------------------------	--	------------------------	-------------	---

Hypromellose with carbomer 980	Ocular lubricating gel 3 mg-2 mg per g, 10 g	Application to the Eye	HPMC PAA	between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand
--------------------------------	--	------------------------	----------	---

33 Schedule 1 (table)

After:

Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Yellow Jacket Venom	6 months stock by reference to usual PBS demand
---	--	-----------	---------------------------------	---

insert:

Irbesartan	Tablet 75 mg	Oral	Karvea	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
------------	--------------	------	--------	--

34 Schedule 1 (table)

After:

Itraconazole	Capsule 100 mg	Oral	APO-Itraconazole	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand
--------------	----------------	------	------------------	--

insert:

Labetalol	Tablet containing labetalol hydrochloride 100 mg	Oral	Presolol 100	between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand
-----------	--	------	--------------	--

35 Schedule 1 (table)

Omit:

Lisinopril	Tablet 20 mg	Oral	Lisinopril generichealth	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
------------	--------------	------	-----------------------------	--

36 Schedule 1 (table)

After:

Lithium	Tablet containing lithium carbonate 450 mg (slow release)	Oral	Quilonum SR	6 months stock by reference to usual PBS demand
---------	--	------	-------------	---

insert:

Macrogol 3350	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	Oral	Movicol	between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand
---------------	---	------	---------	--

37 Schedule 1 (table)

Omit:

Meloxicam	Tablet 15 mg	Oral	Pharmacor Meloxicam 15	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-----------	--------------	------	---------------------------	--

38 Schedule 1 (table)

Omit:

Meloxicam	Tablet 7.5 mg	Oral	Pharmacor Meloxicam 7.5	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-----------	---------------	------	----------------------------	--

39 Schedule 1 (table)

Omit:

Methylprednisolone	Injection containing methylprednisolone acetate 40 mg in 1 mL	Injection	Depo-Nisolone	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
--------------------	--	-----------	---------------	--

40 Schedule 1 (table)

	After:				
Nevirapine	Tablet 200 mg	Oral	Nevirapine Viatris	after 30 November 2024—4 months stock by reference to usual demand of both Nevirapine Viatris and Nevirapine Alphapharm added together	
	insert:				
Nevirapine	Tablet 400 mg (extended release)	Oral	Viramune XR	between 1 October 2024 and 30 September 2025—0 months stock by reference to usual demand	

41 Schedule 1 (table)

	After:				
Norfloxacin	Tablet 400 mg	Oral	APO-Norfloxacin	2.5 months stock by reference to usual demand	
	insert:				
Nortriptyline	Tablet 10 mg (as hydrochloride)	Oral	NortriTABS 10 mg	between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand	
Nortriptyline	Tablet 25 mg (as hydrochloride)	Oral	NortriTABS 25 mg	between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand	

42 Schedule 1 (table)

	After:				
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	Acpio 45	between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand	
	insert:				
Pregabalin	Capsule 150 mg	Oral	Cipla Pregabalin	between 1 October 2024 and 28 February 2025—0 months stock by reference to usual demand	

43 Schedule 1 (table)

Omit:

Riluzole	Oral suspension 50 mg per 10 mL, 300 mL	Oral	Teglutik	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
----------	---	------	----------	--

44 Schedule 1 (table)

Omit:

Rizatriptan	Tablet (orally disintegrating) 10 mg (as benzoate)	Oral	APO-Rizatriptan	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-------------	--	------	-----------------	---

Rizatriptan	Tablet (orally disintegrating) 10 mg (as benzoate)	Oral	Rizatriptan ODT GH	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-------------	--	------	--------------------	---

45 Schedule 1 (table)

Omit:

Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Viread	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-----------	--	------	--------	---

46 Schedule 1 (table)

Omit:

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg	Oral	Tenofovir EMT GH	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
------------------------------	---	------	------------------	---

47 Schedule 1 (table)

Omit:

Valaciclovir	Tablet 500 mg (as hydrochloride)	Oral	Valacor 500	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------	----------------------------------	------	-------------	---

48 Schedule 1 (table)

Omit:

Zoledronic acid	Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL	Injection	Zoledronic Acid SUN	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
-----------------	--	-----------	---------------------	---

**Schedule 2—Amendments commencing immediately after
the commencement of Schedule 2 to the *National
Health (Minimum Stockholding) Amendment
Determination (No. 4) 2024 – 1 October 2024***

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

Amino acid formula with vitamins and minerals without lysine and low in tryptophan	Sachets containing oral powder 24 g, 30 (GA gel)	Oral	GA gel	6 months stock by reference to usual PBS demand
--	--	------	--------	---

substitute:

Amino acid formula with vitamins and minerals without lysine and low in tryptophan	Sachets containing oral powder 24 g, 30 (GA gel)	Oral	GA gel	0 months stock by reference to usual PBS demand
--	--	------	--------	---

2 Schedule 1 (table)

After:

Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	Oral	AVSARTAN HCT 150/12.5	4 months stock by reference to usual demand
-------------------------------------	-----------------------	------	-----------------------	---

insert:

Isoleucine with carbohydrate	Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000)	Oral	Isoleucine 1000	0 months stock by reference to usual PBS demand
Isoleucine with carbohydrate	Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)	Oral	Isoleucine 50	0 months stock by reference to usual PBS demand

**Schedule 3—Amendments commencing immediately after
the commencement of Schedule 3 to the *National
Health (Minimum Stockholding) Amendment
Determination (No. 6) 2024 – 1 December 2024***

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

Valine with carbohydrate	Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000)	Oral	Valine 1000	6 months stock by reference to usual PBS demand
-----------------------------	---	------	-------------	---

substitute:

Valine with carbohydrate	Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000)	Oral	Valine 1000	0 months stock by reference to usual PBS demand
-----------------------------	---	------	-------------	---

2 Schedule 1 (table)

Omit:

Valine with carbohydrate	Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50)	Oral	Valine 50	6 months stock by reference to usual PBS demand
-----------------------------	--	------	-----------	---

substitute:

Valine with carbohydrate	Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50)	Oral	Valine 50	0 months stock by reference to usual PBS demand
-----------------------------	--	------	-----------	---